Milestone Pharmaceuticals (Milestone Pharmaceuticals) Retained Earnings : $-336.38 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Milestone Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Milestone Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2024 was $-336.38 Mil.

Milestone Pharmaceuticals's quarterly retained earnings declined from Sep. 2023 ($-312.42 Mil) to Dec. 2023 ($-326.03 Mil) and declined from Dec. 2023 ($-326.03 Mil) to Mar. 2024 ($-336.38 Mil).

Milestone Pharmaceuticals's annual retained earnings declined from Dec. 2021 ($-207.95 Mil) to Dec. 2022 ($-266.34 Mil) and declined from Dec. 2022 ($-266.34 Mil) to Dec. 2023 ($-326.03 Mil).

Milestone Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Milestone Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Milestone Pharmaceuticals Retained Earnings Chart

Milestone Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-113.50

-163.47

-207.95

-266.34

-326.03

Milestone Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-281.29	-297.33	-312.42	-326.03	-336.38

Milestone Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Milestone Pharmaceuticals (NAS:MIST) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Milestone Pharmaceuticals (Milestone Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Milestone Pharmaceuticals Inc (NAS:MIST) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, QC, CAN, H4M 2X6

Website

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.

Executives

Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
David Bharucha	officer: Chief Medical Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Debra K. Liebert	director	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6
Richard C Pasternak	director	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jeffrey Edward Nelson	officer: Chief Operating Officer	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Novo Holdings A/s	10 percent owner, other: SEE REMARKS	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Amit Hasija	officer: CFO & EVP of Corp. Development	C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6
Lorenz Muller	officer: Chief Commercial Officer	C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6